Tarsus Pharmaceuticals (TARS) Free Cash Flow (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Free Cash Flow of -$25.6 million for Q1 2026, down 20.35% year-over-year from -$32.1 million in Q1 2025, and down 333.03% quarter-over-quarter from $11.0 million in Q4 2025.
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) Free Cash Flow (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$25.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 20.35% year-over-year to -$25.6 million; the TTM figure through Mar 2026 stood at -$26.6 million (up 60.76% YoY), while the FY2025 annual figure was -$22.3 million, up 73.63% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$25.6 million, down from $11.0 million in the prior quarter.
- The five-year high for Free Cash Flow was $18.3 million in Q3 2025, with the low at -$38.6 million in Q4 2023.
- The 5-year median for Free Cash Flow is -$21.2 million (2025), against an average of -$17.6 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow sank 509.84% in 2022, then surged 297.32% in 2025.
- Tarsus Pharmaceuticals' Free Cash Flow stood at -$11.0 million in 2022, then sank by 250.02% to -$38.6 million in 2023, then jumped by 38.55% to -$23.7 million in 2024, then jumped by 146.3% to $11.0 million in 2025, then tumbled by 333.03% to -$25.6 million in 2026.
- Business Quant data shows TARS's Free Cash Flow at -$25.6 million in Q1 2026, $11.0 million in Q4 2025, and $18.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn | 57.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 57.15 Mn |
| Mar 31, 2026 | -30.47 Mn |
| Dec 31, 2025 | 12.97 Mn |
| Sep 30, 2025 | 16.35 Mn |
| Jun 30, 2025 | -30.39 Mn |
| Mar 31, 2025 | -21.24 Mn |
| Dec 31, 2024 | -22.25 Mn |
| Sep 30, 2024 | -8.93 Mn |
| Jun 30, 2024 | -15.44 Mn |
| Mar 31, 2024 | -37.96 Mn |
| Dec 31, 2023 | -39.34 Mn |
| Sep 30, 2023 | -32.74 Mn |
| Jun 30, 2023 | -24.61 Mn |
| Mar 31, 2023 | -22.31 Mn |
| Dec 31, 2022 | -11.00 Mn |
| Sep 30, 2022 | -18.71 Mn |
| Jun 30, 2022 | -4.38 Mn |
| Mar 31, 2022 | -15.45 Mn |
| Dec 31, 2021 | -11.62 Mn |
| Sep 30, 2021 | 6.68 Mn |